Gwenn Hansen
Chief Scientific Officer at Nurix Therapeutics, Inc. (NRIX)
Purchase track record
Not enough history. Based on 0 purchases with a full 90 days of price history.
—
Avg. 90-day return—
vs. S&P 500—
Beat the market—
Paper profit on buys$0
Total bought / sold$0 / $631K
Reported trades
| Filed | Stock | Type | Shares | Price | Value | Since |
|---|---|---|---|---|---|---|
| Sep 1SEC | NRIXNurix Therapeutics, Inc. | Sell Plan | 1,452117,227 held (−1%) | $25.47 | $37K | -12.2% |
| Aug 5SEC | NRIXNurix Therapeutics, Inc. | Sell Plan | 1,500119,838 held (−1%) | $23.87 | $36K | -6.4% |
| Aug 5SEC | NRIXNurix Therapeutics, Inc. | Sell Plan | 2,611117,227 held (−2%) | $24.64 | $64K | -9.3% |
| Aug 5SEC | NRIXNurix Therapeutics, Inc. | Sell Plan | 4,356117,227 held (−4%) | $25.00 | $109K | -10.6% |
| Jul 30SEC | NRIXNurix Therapeutics, Inc. | Sell | 3,847121,338 held (−3%) | $23.38 | $90K | -4.4% |
| Jun 25SEC | NRIXNurix Therapeutics, Inc. | Sell Plan | 5,394115,005 held (−4%) | $20.00 | $108K | +11.8% |
| Apr 30SEC | NRIXNurix Therapeutics, Inc. | Sell | 3,214120,399 held (−3%) | $16.65 | $54K | +34.2% |
| Jan 30SEC | NRIXNurix Therapeutics, Inc. | Sell | 4,79783,770 held (−5%) | $16.58 | $80K | +34.8% |
| Jan 30SEC | NRIXNurix Therapeutics, Inc. | Sell | 9883,672 held (−0%) | $17.37 | $2K | +28.7% |
| Oct 30SEC | NRIXNurix Therapeutics, Inc. | Sell | 4,08776,751 held (−5%) | $12.80 | $52K | +74.6% |
- Sell
Chief Scientific Officer Gwenn Hansen sold $37K of NRIX at $25.47 — pre-scheduled 10b5-1 plan sale.
- Sell
Chief Scientific Officer Gwenn Hansen sold $36K of NRIX at $23.87 — pre-scheduled 10b5-1 plan sale.
- Sell
Chief Scientific Officer Gwenn Hansen sold $64K of NRIX at $24.64 — pre-scheduled 10b5-1 plan sale.
- Sell
Chief Scientific Officer Gwenn Hansen sold $109K of NRIX at $25.00 — pre-scheduled 10b5-1 plan sale.
- Sell
Chief Scientific Officer Gwenn Hansen sold $108K of NRIX at $20.00 — pre-scheduled 10b5-1 plan sale.